Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study)

European Journal of Cancer

Volumn 48, Issue 17, 2012, Pages 3205-3214

  Lebbe, C ^a   Lorigan, P ^b   Ascierto, P ^c   Testori, A ^d   Bedane C ^e   Middleton, M ^f   Van Baardewijk, M ^g   Konto, C ^g   Dueymes, A ^h   Maio, M ⁱ  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e DUPUYTREN UNIVERSITY HOSPITAL   (France)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g BRISTOL MYERS SQUIBB   (United States)

^h PAREXEL INTERNATIONAL   (United States)

ⁱ UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Longitudinal survey; Melanoma; Metastasis; Overall survival; Patient outcomes assessment; Retrospective study; Systemic; Treatment

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EUROPE; FEMALE; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; LACTATE DEHYDROGENASE BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE;

BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84868213746     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.05.010     Document Type: Article

References (23)

1. R. Dummer, A. Hauschild, and G. Pentheroudakis Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 4 2009 129 131
2. C. Garbe, K. Peris, and A. Hauschild Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline Eur J Cancer 46 2 2010 270 283
3. C.M. Balch, A.C. Buzaid, and S.J. Soong Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 16 2001 3635 3648
4. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
5. L. Chin, L.A. Garraway, and D.E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era Genes Dev 20 16 2006 2149 2182
6. L.M. Jost, S. Jelic, and G. Purkalne ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma Ann Oncol 16 Suppl. 1 2005 i66 i68
7. Cameron D, Cooper M, Haward R, et al. Four-fold increase in recruitment of cancer patients to NCRN portfolio studies between 2001 and 2010: a tale of investment bringing returns. National Cancer Research Institute Cancer Conference; Abstract C64. < http://www.ncri.org.uk/ncriconference/ 2010abstracts/abstracts/C64.htm >; 2010.
8. G. Sinha United Kingdom becomes the cancer clinical trials recruitment capital of the world J Natl Cancer Inst 99 6 2007 420 422
9. R. Dummer, A. Hauschild, and M. Guggenheim Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v194 v197
10. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 10 2004 998 1012
11. E.L. Korn, P.Y. Liu, and S.J. Lee Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials J Clin Oncol 26 4 2008 527 534
12. M.F. Avril, S. Aamdal, and J.J. Grob Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J Clin Oncol 22 6 2004 1118 1125
13. M.R. Middleton, J.J. Grob, and N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 1 2000 158 166
14. J. Manola, M. Atkins, and J. Ibrahim Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials J Clin Oncol 18 22 2000 3782 3793
15. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
16. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E Mutation N Engl J Med 364 26 2011 2507 2516
17. Zelboraf SmPC EU. Summary of product characteristics. < http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002409/WC500124320.pdf >.
18. I. Ray-Coquard, C. Cropet, and G.M. Van Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas Cancer Res 69 13 2009 5383 5391
19. I.J. Fidler, G. Schackert, and R.D. Zhang The biology of melanoma brain metastasis Cancer Metastasis Rev 18 3 1999 387 400
20. M. Staudt, K. Lasithiotakis, and U. Leiter Determinants of survival in patients with brain metastases from cutaneous melanoma Br J Cancer 102 8 2010 1213 1218
21. S.S. Agarwala, J.M. Kirkwood, and M. Gore Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study J Clin Oncol 22 11 2004 2101 2107
22. D. Schadendorf, A. Hauschild, and S. Ugurel Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study Ann Oncol 17 10 2006 1592 1597
23. S. Siena, L. Crino, and M. Danova Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study Ann Oncol 21 3 2010 655 661